The morcellation controversy heats up as physicians all over the world who use Ethicon power morcellators are being asked to return the medical devices.
Earlier this year, Johnson & Johnson’s Ethicon unit suspended sales and distribution of its power morcellators. J&J is now calling for “a worldwide market withdrawal” of any Ethicon morcellation devices, and they are asking their customers-physicians and hospitals-to return any and all of these devices that have already been purchased. The company is issuing a credit for all devices returned before December 30, 2014. (
to see the letter.)
J&J’s decision comes after the FDA has recommended that the use of these devices be suspended until further review of the risk of these devices inadvertently spreading an unknown cancer in women with fibroids.
"Due to this continued uncertainty, Ethicon believes that a market withdrawal of Ethicon morcellation devices is the appropriate course of action at this time until further medical guidelines are established and/or new technologies are developed to mitigate the risk," the company said in an e-mailed statement to Reuters, as reported in this Huffington Post article.
How will this impact your practice, and what do you think about this recall?
(We invite you to share your thoughts in the Comment Section below.)
PCOS and irregular cycles tied to cardiometabolic risks
May 15th 2024A comprehensive analysis reveals strong associations between polycystic ovary syndrome, irregular menstrual cycles, and increased risks of cardiometabolic conditions, underscoring the importance of proactive screening and intervention strategies.
Read More
Postmenopausal urinary incontinence treatment data found lacking
May 6th 2024Discover the findings of a comprehensive study exploring the efficacy of various treatments for postmenopausal urinary incontinence, shedding light on the current research gap and recommending avenues for future investigation.
Read More
Pioglitazone outperforms metformin in IVF for PCOS-related infertility
May 6th 2024A recent double-blind, randomized clinical trial revealed a higher clinical pregnancy rate with pioglitazone compared to metformin in polycystic ovarian syndrome patients undergoing in vitro fertilization, suggesting potential for improved outcomes.
Read More
Advancing obstetric and gynecologic surgery through robotic innovation
April 30th 2024Explore how robotic surgery revolutionizes obstetric and gynecologic procedures, offering enhanced precision, reduced complications, and improved patient outcomes, while also examining challenges and future prospects in the field.
Read More